Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research

Generate Biomedicines (NASDAQ:GENB) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other equities analysts also recently issued reports on GENB. Wall Street Zen upgraded shares of Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. Morgan Stanley assumed coverage on shares of Generate Biomedicines in a research report on Tuesday. They set an “overweight” rating and a $20.00 price target for the company. Guggenheim assumed coverage on Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $30.00 price target on the stock. The Goldman Sachs Group began coverage on Generate Biomedicines in a report on Tuesday. They set a “buy” rating and a $26.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on Generate Biomedicines in a report on Tuesday. They issued an “overweight” rating on the stock. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Generate Biomedicines currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Generate Biomedicines Stock Up 8.6%

Generate Biomedicines stock opened at $12.85 on Wednesday. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.